Sarah Premji, Clinical Oncology Fellow at Mayo Clinic, shared a post on X:
”lidERA – ER+/HER2- eBC – showed 3 year iDFS 92.4% with GIRE vs 89.6% SOC ET.
Looked at by menopausal status, premenopausal 41%, post menopausal 59%, pre menopausal iDFS 94% with GIRE vs 91.5% SOC ET, HR 0.65, in post menopausal, 91.3% with GIRE vs 88.3% with SOC ET HR 0.74, improvement also in DFRI in both groups, also fewer pts switched to alternative ET compared to SOC ET and fewer d/c for AE in GIRE vs SOC ET.
Doesn’t appear OFS significantly impacts change in MSK symptoms by way of breakdown by menopausal status.”
Other Articles Featuring Sarah Premji On OncoDaily.